L-Alanine

Pharmacology & Research

L-Alanine is a small, nonessential (dispensable) alpha-amino acid that the body synthesises readily from pyruvate, and it is the pivotal nitrogen carrier of the glucose–alanine (Cahill) cycle — the loop by which working muscle exports amino nitrogen to the liver and the liver returns glucose. Because the body makes and recycles alanine so efficiently, almost all of the credible research concerns its physiological role or its use as a functional ingredient (a gluconeogenic substrate, a co-transported solute in rehydration fluids), not a benefit from taking it as a standalone pill in already-adequate people. The strongest human data sit in narrow clinical niches — fortified oral rehydration solutions and condition-specific hypoglycaemia — and even there the results are mixed. A recurring caveat runs through the popular literature: most sports “alanine” products are actually beta-alanine, a structurally different, non-proteinogenic molecule, and evidence for one does not transfer to the other.

1. Oral rehydration (alanine-fortified ORS)

L-Alanine is absorbed across the intestinal brush border by a sodium-coupled transporter, and in animal and Ussing-chamber work adding alanine to a glucose solution increases net sodium and water absorption — including in virally damaged jejunum ^{8,9Reference 8Rhoads et al. · 1986Alanine enhances jejunal sodium absorption in the presence of glucose — animal studyView study →Reference 9Sarker et al. · 1995RCTAlanine- and glucose-based hypo-osmolar oral rehydration solution in infants with persistent diarrhoea — randomised controlled trialView study →}. This is the rationale for “super-ORS.” In a double-blind randomised trial in adults with severe cholera/ETEC dehydration (n=97), an alanine-plus-glucose ORS reduced stool output and ORS requirement versus standard WHO-ORS ^{11Reference 11Patra et al. · 1989RCTOral rehydration formula containing alanine and glucose for treatment of diarrhoea — randomised double-blind controlled trialView study →}. However, in acute non-cholera paediatric diarrhoea the added benefit largely disappeared: a randomised infant trial found alanine ORS did not reduce purging versus standard ORS ^{7Reference 7Ribeiro Júnior et al. · 1991RCTAlanine-based oral rehydration therapy for infants with acute diarrhea — randomised trialView study →}, and a further randomised, double-blind paediatric trial of alanine ORS in acute non-cholera diarrhoea likewise found no clear clinical advantage over standard ORS ^{12Reference 12Sazawal et al. · 1991RCTAlanine-based oral rehydration solution: assessment of efficacy in acute noncholera diarrhea among children — randomised double-blind trialView study →}, while WHO’s own review of glycine-, alanine-, glutamine-, maltodextrin- and rice-based formulations concluded the amino-acid additions did not provide a reliable advantage in non-cholera diarrhoea ^{14Reference 14Bhan et al. · 1994Clinical trialClinical trials of improved oral rehydration salt formulations: a reviewView study →}. Interest in amino-acid ORS continues (e.g. multi-amino-acid formulations under formal trial) ^{15Reference 15Das et al. · 2022RCTA double-blind clinical trial to compare a multiple amino acid-based ORS with standard WHO-ORS in non-cholera acute watery diarrhea — trial protocolView study →}, but for the common cause of childhood diarrhoea, alanine fortification has not displaced low-osmolarity glucose ORS.

Gap: benefit is real in high-purging cholera but inconsistent-to-null in the far more common non-cholera diarrhoea; effect is a property of the fluid formulation, not of oral alanine taken by well people.

2. Nocturnal hypoglycaemia (type 1 diabetes)

Because alanine is a glucagon secretagogue and gluconeogenic precursor, it has been tested as a sustained overnight glucose source. In a four-way crossover study of 15 patients with insulin-dependent diabetes, a bedtime dose of 40 g L-alanine (plus 10 g glucose, ~200 kcal) raised plasma glucose and reduced early-night hypoglycaemia compared with no treatment, performing comparably to a standard snack and to terbutaline ^{5Reference 5Saleh et al. · 1997RCTAlanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDM — randomised crossover trialView study →}. The effect is plausible and consistent with alanine’s endocrine action ^{3,4Reference 3Müller et al. · 1971Clinical trialThe effect of alanine on glucagon secretion — animal/human studyView study →Reference 4Martineau et al. · 1985Simultaneous determination of glucose turnover, alanine turnover, and gluconeogenesis in humans — stable-isotope tracer studyView study →}, but rests on a single small, short-duration trial in a specific patient group and requires a large (40 g) dose.

Gap: one small crossover trial only; a condition-specific (disease-dependent) use at a high dose, never replicated at scale, and not a general benefit.

3. Gluconeogenic support in glycogen storage disease

In disorders where hepatic glucose release is impaired (e.g. debrancher/GSD III), patients rely heavily on gluconeogenesis, and alanine is the principal gluconeogenic amino acid extracted by the liver ^{1,4Reference 1Felig · 1973ReviewThe glucose-alanine cycle — reviewView study →Reference 4Martineau et al. · 1985Simultaneous determination of glucose turnover, alanine turnover, and gluconeogenesis in humans — stable-isotope tracer studyView study →}. A classic case report showed that high-protein nocturnal feeding — supplying gluconeogenic substrate — reversed myopathy, hypoglycaemia and growth failure in a child with debrancher deficiency ^{6Reference 6Slonim et al. · 1982Case reportReversal of debrancher deficiency myopathy by the use of high-protein nutrition — case reportView study →}. Here alanine is best understood as one component of a protein/substrate strategy rather than a proven standalone supplement.

Gap: mechanism-plus-case-report evidence in a rare disease; the intervention is high-protein nutrition, not isolated L-alanine, and none of it generalises to healthy people.

4. Benign prostatic hyperplasia (amino-acid blend)

A glycine–alanine–glutamic acid combination (“Paraprost”) was marketed decades ago for benign prostatic symptoms, with early uncontrolled reports of symptom relief ^{10Reference 10Feinblatt et al. · 1958Palliative treatment of benign prostatic hypertrophy; value of glycine-alanine-glutamic acid combinationView study →}. Later controlled work found it far weaker than an alpha-blocker: in a double-blind study prazosin improved flow rates while the amino-acid product left them essentially unchanged ^{13Reference 13Yamaguchi et al. · 1990RCTClinical evaluation of prazosin in benign prostatic obstruction; Paraprost-controlled double-blind studyView study →}. This is a combination product, not standalone L-alanine, and modern urology does not use it.

Gap: old, largely uncontrolled data on a three-amino-acid blend; not isolated alanine, and outclassed by standard pharmacotherapy.

Mechanisms

Target / pathway	Effect	Relevant to
Alanine aminotransferase (ALT) / transamination	Transfers amino group between pyruvate and glutamate; interconverts alanine ⇄ pyruvate	Glucose–alanine cycle, nitrogen transport
Hepatic gluconeogenesis	Alanine → pyruvate → glucose; principal gluconeogenic amino acid	Fasting/exercise glucose supply, GSD, hypoglycaemia
Pancreatic alpha-cell (glucagon secretion)	Alanine stimulates glucagon release	Counter-regulation, hypoglycaemia prevention
Intestinal Na⁺-coupled amino-acid transport	Co-transport of alanine with Na⁺ drives water absorption	Oral rehydration solutions

Pharmacokinetics

Dietary and supplemental L-alanine is absorbed rapidly and near-completely in the small intestine via sodium-dependent neutral-amino-acid transporters (and, as dipeptides, via PepT1), and enters the portal circulation. It is a highly dynamic pool: plasma alanine rises with exercise as muscle exports nitrogen ^{2Reference 2Brodan et al. · 1976Clinical trialChanges of free amino acids in plasma of healthy subjects induced by physical exercise — human studyView study →} and falls during fasting as the liver consumes it for gluconeogenesis. Because the body synthesises alanine from pyruvate and clears it briskly through transamination and gluconeogenesis, an oral dose does not produce a sustained, drug-like exposure — its metabolic fate is to be turned into glucose, urea nitrogen, or protein. There is no established “half-life” in the pharmacological sense; turnover is fast and tightly coupled to whole-body glucose and nitrogen flux ^{1,4Reference 1Felig · 1973ReviewThe glucose-alanine cycle — reviewView study →Reference 4Martineau et al. · 1985Simultaneous determination of glucose turnover, alanine turnover, and gluconeogenesis in humans — stable-isotope tracer studyView study →}.

Clinical trials

Registered/published trial activity is modest and clustered in oral rehydration and metabolic physiology; there is little industry-funded standalone-supplement trial activity, as alanine is an unpatentable dietary amino acid. Most “alanine” performance trials in registries are in fact beta-alanine studies and are not counted here.

Last checked: July 2026.

Dietary Sources

L-Alanine is abundant in virtually all protein-containing foods and, unlike essential amino acids, is also synthesised by the body from pyruvate — so dietary intake is rarely a limiting factor. It is well represented in meat, poultry, fish, eggs, dairy, and in plant proteins such as legumes, soy, nuts, seeds and whole grains. Gelatin and other connective-tissue proteins are particularly rich in alanine. There is no meaningful risk of dietary deficiency in anyone eating adequate protein.

Food group	Typical alanine content	Notes
Meat, poultry, fish	High	~1–1.5 g per 100 g cooked protein-rich portion
Eggs, dairy	Moderate–high	Complete protein; steady contributor
Legumes, soy	Moderate–high	Main plant source
Nuts, seeds, whole grains	Moderate	Contributes across a mixed diet
Gelatin / collagen	Very high	One of the more alanine-dense proteins

Amounts are approximate; alanine tracks total protein intake. Because the body synthesises alanine, dietary supply is not considered rate-limiting in health. (No dedicated NIH ODS fact sheet exists for individual nonessential amino acids.)

Dosage

There is no RDA, Adequate Intake, or Tolerable Upper Intake Level for L-alanine — as a nonessential amino acid it is not assigned a dietary reference value, and adequacy is met through ordinary dietary protein. Standalone L-alanine supplementation is uncommon; the amino acid mainly appears within complete-protein powders, amino-acid blends, and clinical/parenteral nutrition. The largest doses in the research literature are experimental rather than recommended: e.g. a single bedtime dose of ~40 g was used to study nocturnal hypoglycaemia in type 1 diabetes ^{5Reference 5Saleh et al. · 1997RCTAlanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDM — randomised crossover trialView study →}, and alanine has been added to oral rehydration fluids at defined millimolar concentrations (e.g. 30–90 mmol/L) ^{7,9,12Reference 7Ribeiro Júnior et al. · 1991RCTAlanine-based oral rehydration therapy for infants with acute diarrhea — randomised trialView study →Reference 9Sarker et al. · 1995RCTAlanine- and glucose-based hypo-osmolar oral rehydration solution in infants with persistent diarrhoea — randomised controlled trialView study →Reference 12Sazawal et al. · 1991RCTAlanine-based oral rehydration solution: assessment of efficacy in acute noncholera diarrhea among children — randomised double-blind trialView study →}.

These are doses studied in research, not a personal recommendation. For general health there is no evidence that supplementing L-alanine on top of an adequate-protein diet confers benefit.

Safety

L-Alanine is a normal constituent of dietary protein and is generally regarded as safe at the levels obtained from food. Standalone supplementation is uncommon, so high-quality safety and dose-limiting data are sparse; the large experimental doses used in hypoglycaemia research (~40 g) were given acutely without reported serious adverse effects, but long-term high-dose safety has not been characterised. The most important practical caution is one of identity, not toxicity: L-alanine is frequently confused with beta-alanine, a different molecule whose hallmark side effect (paraesthesia — skin tingling) does not apply to L-alanine. As with any amino acid, people with significant hepatic or renal impairment — who have limited capacity to handle nitrogen loads — should be cautious with large supplemental amino-acid doses and seek clinical guidance. Anyone considering supplementation for a medical condition (e.g. glycaemic management) should consult a qualified healthcare professional, as this is not a self-treatment context.

Pregnancy & lactation

Verdict: no specific safety concern at dietary levels; no data to support standalone high-dose supplementation. L-Alanine from food is part of normal maternal and fetal amino-acid metabolism and poses no known risk. There is no evidence base for taking isolated L-alanine supplements during pregnancy or breastfeeding, so supplementation beyond dietary intake is not advised without medical supervision.

Scope disclosure (REQUIRED honesty — not a claim, no citation):

• Interactions assessed? Partially — no clinically significant drug interactions are established for L-alanine; it is not a substrate/inhibitor of major drug-metabolising pathways. Formal interaction studies are lacking.
• Pregnancy/lactation assessed? Not formally in a supplemental context — safe as a dietary component; no trials of isolated supplementation.
• Upper Limit (UL) established? No UL set. Absence of a UL does not imply that unlimited intake is safe; it reflects that the compound has not been formally evaluated for one.

Never imply safety from absence of reports. Where it wasn’t studied, it is marked “not assessed.”

References